Page last updated: 2024-08-18

pyridostigmine bromide and Infections, Coronavirus

pyridostigmine bromide has been researched along with Infections, Coronavirus in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Govindarajan, R; Singh, S	1
Koc, G; Odabasi, Z; Tan, E	1
Arias-Martínez, S; Audelo-Cruz, BM; Belaunzarán-Zamudio, PF; Calva, JJ; Carbajal-Morelos, SL; Caro-Vega, Y; Crabtree-Ramírez, B; Crispín, JC; Fragoso-Saavedra, S; García-González, HB; González-Duarte, A; Iruegas-Nunez, DA; Luqueño-Martínez, V; Nuñez, I; Quintero-Villegas, A; Sierra-Madero, J; Valdés-Ferrer, SI	1

Trials

1 trial(s) available for pyridostigmine bromide and Infections, Coronavirus

Article	Year
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 inf BMC infectious diseases, 2020, Oct-16, Volume: 20, Issue:1 Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Humans; Inflammation; Lung; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; Respiration, Artificial; SARS-CoV-2	2020

Article

Year

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 inf

BMC infectious diseases, 2020, Oct-16, Volume: 20, Issue:1

Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Humans; Inflammation; Lung; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; Respiration, Artificial; SARS-CoV-2

2020

Other Studies

2 other study(ies) available for pyridostigmine bromide and Infections, Coronavirus

Article	Year
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report. Clinical neurology and neurosurgery, 2020, Volume: 196 Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Disease Progression; Female; Glucocorticoids; Humans; Hypercapnia; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Myasthenia Gravis; Mycophenolic Acid; Pandemics; Plasma Exchange; Pneumonia, Viral; Prednisone; Pyridostigmine Bromide; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index; Thymectomy; Tomography, X-Ray Computed	2020
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis. Journal of clinical neuromuscular disease, 2020, Volume: 22, Issue:1 Topics: Antimalarials; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Male; Middle Aged; Myasthenia Gravis; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; SARS-CoV-2	2020

Article

Year

COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.

Clinical neurology and neurosurgery, 2020, Volume: 196

Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Disease Progression; Female; Glucocorticoids; Humans; Hypercapnia; Hypoxia; Immunoglobulins, Intravenous; Immunologic Factors; Myasthenia Gravis; Mycophenolic Acid; Pandemics; Plasma Exchange; Pneumonia, Viral; Prednisone; Pyridostigmine Bromide; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Severity of Illness Index; Thymectomy; Tomography, X-Ray Computed

2020

Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.

Journal of clinical neuromuscular disease, 2020, Volume: 22, Issue:1

Topics: Antimalarials; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Male; Middle Aged; Myasthenia Gravis; Pandemics; Pneumonia, Viral; Pyridostigmine Bromide; SARS-CoV-2

2020